Spyre Therapeutics showcases positive phase 2 data for SPY001 in ulcerative colitis, opening enrolment for combination cohorts

Spyre Therapeutics has recently reported encouraging Phase 2 data for SPY001, its experimental long-acting antibody for moderate to severely active ulcerative colitis, with results showing the drug hit its primary endpoint and delivered clinically meaningful improvements across key secondary measures at 12 weeks.

Note that n the Part A open-label portion of its SKYLINE trial, SPY001 achieved a statistically significant reduction of 9.2 points in the Robarts Histopathology Index, a measure of gut inflammation assessed by tissue biopsy. Clinical remission was achieved in 40% of patients and endoscopic improvement in 51%, with a well-tolerated safety profile consistent with its drug class.

Deanna Nguyen, SVP of Clinical Development and lead of the SKYLINE study, described the results as supporting the hypothesis that SPY001 could become a best-in-class therapy across safety, efficacy and convenience. She noted the drug was specifically engineered to improve upon vedolizumab, the current standard in gut-selective biologics for IBD, by matching its proven mechanism while extending the drug’s duration in the body to enable far less frequent dosing.

For investors, the appeal goes beyond the monotherapy data. Nguyen highlighted that SPY001’s gut-selective mechanism makes it what the company believes is “an ideal backbone for combination therapy” alongside two other investigational antibodies in Spyre’s pipeline, SPY002 and SPY003, which target different inflammatory pathways. Proof-of-concept data for those combinations are expected to begin emerging from mid-2026 onwards.

Where the Trial Stands Now

Part A of the SKYLINE trial has now closed enrollment ahead of schedule, and Part B has opened. This next phase is both randomised and placebo-controlled, and will assess not only the three monotherapies individually but three pairwise combinations of them, each versus a shared placebo. Part B induction data across all cohorts are expected in 2027.

Sheldon Sloan, Chief Medical Officer at Spyre, credited the pace of enrolment to strong execution by the team and expressed confidence that the positive SPY001 results would drive heightened investigator enthusiasm for Part B, which he described as a “unique opportunity to evaluate perhaps the three most promising combinations in development” for IBD.

The Bigger Picture

Ulcerative colitis affects millions of patients worldwide and represents a market worth tens of billions of dollars annually. Current leading therapies require frequent injections or infusions, creating a significant unmet need for treatments that are both more effective and more convenient. SPY001 is engineered for potential dosing as infrequently as every three to six months via a single subcutaneous injection, which if proven in later trials, would represent a meaningful step forward for patients and a compelling commercial proposition.

---

---

Related Topics and Keywords

Biopharma, HealthcareInnovation, SPY001, SpyreTherapeutics, SYRE, ulcerative colitis, UlcerativeColitis